Sign In
Buy LLY
$1,231.58
+45.87 (+3.87%)
At Close: Aug 10, 2026
Eli Lilly Slashes Guidance After 'Significantly' Missing Quarterly Estimates; Shares Dive
08:55am, Thursday, 04'th Aug 2022
Eli Lilly missed second-quarter expectations and slashed its full-year outlook Thursday, leading LLY stock to crumble. The post Eli Lilly Slashes Guidance After 'Significantly' Missing Quarterly Estim
Eli Lilly stock falls 3% after Q2 top and bottom line results miss Wall Street's forecast
07:21am, Thursday, 04'th Aug 2022
Eli Lilly & Co. LLY, -1.99% shares fell 3.6% in pre-market trading on Thursday after the company reported second-quarter results that came in below Wall Street's forecast. The company's stock ended We
Eli Lilly quarterly profit falls 31% on diabetes drug weakness
06:31am, Thursday, 04'th Aug 2022
Eli Lilly and Co reported a 31% fall in quarterly profit on Thursday, hurt by lower prices of diabetes drug Humalog and Insulin Lispro injection.
Watch These Leaders With Earnings Due, Buy Zones In Focus
01:11pm, Monday, 01'st Aug 2022
With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones. The post Watch These Leaders With Earnings Due, Buy Zones In Focus appeared first on I
AbbVie (ABBV) Q2 Earnings Beat Estimates
01:05pm, Friday, 29'th Jul 2022 Zacks Investment Research
AbbVie (ABBV) delivered earnings and revenue surprises of 1.81% and 0.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
10 Biggest Companies Reporting Q2 Earnings Next Week
05:12am, Friday, 29'th Jul 2022 Investing.com
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
09:45pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Eli Lilly (LLY) closed at $330.80 in the latest trading session, marking a +0.57% move from the prior day.
Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View
04:11pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.
Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline
02:02pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Long It Could Realistically Take to Turn $25,000 Into $1 Million
01:00pm, Thursday, 28'th Jul 2022 The Motley Fool
If you are patient enough, the payoff will be well worth it.
Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline
11:47am, Thursday, 28'th Jul 2022
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Surpasses Q2 Earnings and Revenue Estimates
11:45am, Thursday, 28'th Jul 2022 Zacks Investment Research
Merck (MRK) delivered earnings and revenue surprises of 11.98% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Innoviva (INVA) Misses Q2 Earnings Estimates
09:55pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Innoviva (INVA) delivered earnings and revenue surprises of -90.91% and 4.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B
02:32pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.2
Better Dividend Stock: Pfizer or Eli Lilly?
09:55am, Wednesday, 27'th Jul 2022 The Motley Fool
Both stocks could be winners for long-term investors, but one gets the nod when it comes to dividends.
